Australia's most trusted
source of pharma news
Posted 15 December 2021 AM
In its largest ever acquisition, CSL has announced it will buy Swiss pharma Vifor for US$12.3 billion (AU$17.2 billion) - a deal that adds 10 commercialised products to the Aussie biotech's swag and boosts the company's pipeline by a third.
The all-cash agreement approved by both boards of directors has been in the wind for some time, and values Vifor at US$179.25 per share, or US$11.7 billion. The US$12.3 billion buy price includes an assumed debt of 540 million Swiss francs (US$586 million).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.